The Prostate Cancer Research and Education Foundation, 6823 Deer Hollow PI, San Diego, CA, USA.
Anticancer Res. 2010 Feb;30(2):399-401.
Noscapine has demonstrated potent antitumour activity and minimum toxicity in cancer models. Recently, noscapine has been shown to limit tumour growth and lymphatic metastasis of PC3 human prostate cancer mice. The prophylactic effects of noscapine are not known.
Nude mice received oral noscapine (300 mg/kg per day; 'treatment'; n=10) or diluent ('control'; n=10) for 56 days, beginning 7 days after inoculation with PC3 human prostate cancer cells; or noscapine for 70 days, beginning 7 days before inoculation ('pretreatment'; n=10).
Mean total tumour volumes were 1731.6+/-602.0 mm(3) in the control group, 644.3+/-545.1 mm(3) in the noscapine pretreatment group and 910.9+/-501.1 mm(3) in the noscapine treatment group (p<0.001 pretreatment vs. control, p<0.05 pretreatment vs. control, p<0.001 pretreatment vs. treatment group), with no evidence of toxicity. Noscapine pretreatment and treatment also reduced tumour weight, the incidence of metastasis and primary tumour inhibition rate.
Pretreatment with oral noscapine limited tumour growth and lymphatic metastasis of PC3 human prostate cancer in this mouse model and conferred a significant additional benefit over noscapine treatment in final tumour volume.
纳曲酮在癌症模型中表现出强大的抗肿瘤活性和最小的毒性。最近，纳曲酮已被证明可限制 PC3 人前列腺癌细胞的肿瘤生长和淋巴转移。纳曲酮的预防作用尚不清楚。
裸鼠在接种 PC3 人前列腺癌细胞后第 7 天开始接受口服纳曲酮（300mg/kg/天；“治疗”组，n=10）或稀释剂（“对照”组，n=10）56 天；或在接种前第 7 天开始接受纳曲酮 70 天（“预处理”组，n=10）。
对照组的平均总肿瘤体积为 1731.6+/-602.0mm(3)，纳曲酮预处理组为 644.3+/-545.1mm(3)，纳曲酮治疗组为 910.9+/-501.1mm(3)（预处理组与对照组相比，p<0.001，预处理组与对照组相比，p<0.05，预处理组与治疗组相比，p<0.001），无毒性迹象。纳曲酮预处理和治疗还降低了肿瘤重量、转移发生率和原发性肿瘤抑制率。
在该小鼠模型中，口服纳曲酮预处理可限制 PC3 人前列腺癌的肿瘤生长和淋巴转移，并在最终肿瘤体积方面比纳曲酮治疗具有显著的额外益处。
